Low expression of BEX1 predicts poor prognosis in patients with esophageal squamous cell cancer

  • Authors:
    • Hai‑Tao Geng
    • Zhi‑Wen Cheng
    • Rui‑Juan Cao
    • Zhen‑Bo Wang
    • Shao‑Zhi Xing
    • Chen Guo
    • Feng Wang
    • Chang‑Min Liu
    • Shao‑Shui Chen
    • Yu‑Feng Cheng
  • View Affiliations

  • Published online on: August 17, 2018     https://doi.org/10.3892/or.2018.6647
  • Pages: 2778-2787
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The brain expressed x‑linked gene 1 (BEX1) is a member of the BEX family and is aberrantly expressed in many cancers. However, the clinical significance of BEX1 expression level and its role in the pathology of esophageal squamous cell cancer (ESCC) remain unknown. In the present study, we determined BEX1 expression in the tumor and adjacent normal tissues from 118 ESCC patients by immunohistochemistry and determined the proliferation and growth of ESCC cells following ectopic overexpression of BEX1 in cultured cells and in mouse‑ESCC xenografts. We observed that BEX1 was downregulated in ESCC tissues compared to adjacent normal tissues, and low BEX1 expression was significantly associated with larger ESCC tumor volume (P<0.001), advanced T stage (P=0.011) and advanced clinical stage (P=0.039). Additionally, survival analysis revealed that low expression of BEX1 significantly predicted poor prognosis in patients with ESCC (P<0.001). Multivariate analysis revealed that low BEX1 expression was an independent prognostic factor of poor survival (P=0.039). In vitro analysis revealed that overexpression of BEX1 inhibited ESCC cell proliferation and colony formation. Furthermore, in vivo tumorigenesis assays revealed that ectopic overexpression of BEX1 suppressed ESCC tumor growth in mice. Further immunoblotting analysis demonstrated that BEX1 upregulation led to reduced expression and phosphorylation of NF‑κB p65, indicating inhibition of the NF‑κB signaling pathway by BEX1. Our findings indicated that low BEX1 expression may be an independent prognostic marker for poor survival and may serve as a potential target for ESCC therapy.
View Figures
View References

Related Articles

Journal Cover

November-2018
Volume 40 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Geng HT, Cheng ZW, Cao RJ, Wang ZB, Xing SZ, Guo C, Wang F, Liu CM, Chen SS, Cheng YF, Cheng YF, et al: Low expression of BEX1 predicts poor prognosis in patients with esophageal squamous cell cancer. Oncol Rep 40: 2778-2787, 2018
APA
Geng, H., Cheng, Z., Cao, R., Wang, Z., Xing, S., Guo, C. ... Cheng, Y. (2018). Low expression of BEX1 predicts poor prognosis in patients with esophageal squamous cell cancer. Oncology Reports, 40, 2778-2787. https://doi.org/10.3892/or.2018.6647
MLA
Geng, H., Cheng, Z., Cao, R., Wang, Z., Xing, S., Guo, C., Wang, F., Liu, C., Chen, S., Cheng, Y."Low expression of BEX1 predicts poor prognosis in patients with esophageal squamous cell cancer". Oncology Reports 40.5 (2018): 2778-2787.
Chicago
Geng, H., Cheng, Z., Cao, R., Wang, Z., Xing, S., Guo, C., Wang, F., Liu, C., Chen, S., Cheng, Y."Low expression of BEX1 predicts poor prognosis in patients with esophageal squamous cell cancer". Oncology Reports 40, no. 5 (2018): 2778-2787. https://doi.org/10.3892/or.2018.6647